Praxis stock tanks after mid-stage movement disorder trial miss
Praxis Precision Medicines has missed its goal in a Phase IIb trial after rolling out positive Phase IIa results last year.
The CNS-focused biotech announced Friday morning that the mid-stage trial did not reach statistical significance in the study’s primary endpoint. The Phase IIb trial, examining drug candidate PRAX-944 in patients with a condition called essential tremor, showed the drug induced an average 3.01-point reduction from baseline in a daily living activity score, compared to a 1.44-point reduction from placebo after eight weeks.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.